Kaneka and Eurogentec Join Forces - June 15, 2010
Liège, Belgium - June 15, 2010. Eurogentec is pleased to announce today that its majority shareholders have entered into an agreement with Kaneka by which the latter will acquire a majority stake in Eurogentec S.A. The Delwart Family remains on the Board of Directors as an important minority shareholder.
Through this agreement, Eurogentec becomes the spearhead of Kaneka in the field of genomics, proteomics, and biologics, joining R&D forces within those fields in Japan, Belgium and the United States.
“Thanks to a strong technical and scientific expertise as well as a customer oriented culture, Eurogentec has become a recognized leading solution provider for the Life Science Research, the Diagnostics and the Biologics Contract Manufacturing markets. It is essential that we leverage on our strengths and further reinforce our presence as a supplier of innovative products and services. Joining forces with Kaneka will enable us to accelerate our research and developments in the Life Science sector. This partnership will allow us to reinforce our production capacity in the Biopharmaceuticals contract manufacturing unit as well as our capacity to develop and launch highly technical products that respond to the needs of the Life Science community , including the fast growing molecular Diagnostic market” explains Jean-Pierre Delwart, CEO of Eurogentec.
Dr. Lieven Janssens from Kaneka says : “ we are looking to maintain and develop all activities of Eurogentec, and position this company as our bridgehead in the field of Life Sciences. Our immediate intention is to make a significant investment within Eurogentec in order to increase their capacity in Biopharmaceuticals contract manufacturing unit.”
Jean-Pierre Delwart Eurogentec ‘s CEO will remain aboard the Company in a leading role in continuing to grow Eurogentec ‘s business and facilitating integration with Kaneka. Kaneka intends to maintain and further develop the 5 state-of-the-art facilities of Eurogentec, in Liège (Belgium) (2), in San Diego and Fremont (California), in Toyama (Japan), together with their valued employees.
Kaneka is an innovation-oriented chemical company. Traditionally the company has been active in polymers, fermentation, biotechnology and electronics, as well as other fields. Business activities now span a broad spectrum of markets ranging from plastics, EPS resins, chemicals and foodstuffs to pharmaceuticals, medical devices, electrical and electronic materials and synthetic fibers. The life science related activities are currently one of the strategically important domains for Kaneka. The company has been a pioneer among Japanese chemical companies in establishing overseas operations, beginning in 1970 with a subsidiary in Belgium.
Kaneka Corporation is a company headquartered in Osaka-Japan, with subsidiaries in Belgium, the United States, Singapore, Malaysia, China, Australia and Vietnam. Net sales in the last financial year were 412 billion Yen, corresponding to about 3.7 billion Euro. Kaneka employs more than 7 700 people worldwide.
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.